In this issue of the journal, the study by Castronovo et al. on the binding of the natural anti-a-galactosyl IgG (antiGal) antibody to human mammary carcinoma cell lines and to cells of primary malignant mammary lesions poses two challenging questions, (a) Is the expression of the Galal3Gal epitopes a common characteristic of human malignant cells? (b) Does anti-Gal bind in vivo to these cells and affect ,the growth and metastatic potential of tumor cells expressing the Galal-3Gal carbohydrate epitope?
Anti-Gal is a natural IgG antibody present in unusually large amounts in the serum of healthy individuals and constitutes 1% of circulating IgG (7). Anti-Gal, which can be readily isolated from normal human AB sera by affinity chromatography, was found to be a polyclonal monospecific antibody interacting specifically with an oligosaccharide residue with the structure Galal-3Gal/31-4GlcNAc-R (2,5). Anti-Gal is produced throughout life in humans as a result of what seems to be a constant antigenic stimulation by gastrointestinal bacteria (e.g., Escherichia coli and fOebsiella), which express a-galactosyl epitopes on their lipopolysaccharides and other cell wall components (4) . A striking reciprocal evolutionary pattern in the distribution of anti-Gal and the Galal-3Gal/31-4GlcNAc-R residue was observed in mammals. The Galal-3Gal/?l-4GlcNAc-R residue is abundant on various nucleated cells and red blood cells from nonprimate mammals, prosimians (i.e., lemurs), and New World monkeys (5, 6) . The expression of this structure is diminished, however, on cells of Old World monkeys, apes, and humans (5, 6) . In contrast, anti-Gal is present in the serum of Old World monkeys and apes in amounts comparable to those found in man, but this antibody is absent from the blood of New World monkeys and various nonprimate mammals (6) . The lack of Galal-3Gal01-4GlcNAc-R synthesis in human cells results from the diminished activity of the enzyme al-3-galactosyltransferase, which catalyzes the following reaction:
Gal/31-4GlcNAc-R + UDP-GalGalal-3Gal01-4GlcNAc-R + UDP.
This enzyme was found to be active in the Golgi apparatus of many mammalian species (7-10), but it was not detected in human cells (5) . It seems that the al-3-galactosyltransferase has undergone suppression in Old World primates. This might have resulted from the exposure of ancestral Old World primates to an infectious agent, endemic to the Old World, which expressed a-galactosyl residues and exerted a deleterious effect on the animals. Such an infectious agent could have driven the ancestors of Old World primates to produce anti-Gal as a protective antibody, with concomitant suppression of the al-3-galactosyltransferase gene activity to prevent autoimmune reactions. The ultimate direct proof for this hypothesis may be obtained by the use of cloned al-3-galactosyltransferase cDNA in hybridization experiments with human DNA to demonstrate the presence of this gene within the human genome. Nevertheless, the present study by Castronovo et al. suggests that the al-3-galactosyltransferase gene is indeed present in man and that this gene appears to undergo deregulation in a considerable proportion of transformed cells in patients with mammary carcinoma. This leads to the synthesis of the Galal-3Gal/?l-4GlcNAc-R epitope in malignant cells, which is recognized by anti-Gal.
The In addition to the basic scientific interest in the possible deregulation of al-3-galactosyltransferase in human malignant cells, this process may also be of considerable clinical significance. Since all humans produce large amounts of antibodies which recognize the Galal-3Gal/}l-4GlcNAc-R epitope (i.e., the anti-Gal antibodies), it may be assumed that expression of such epitopes would be detrimental to malignant cells. This assumption has been evaluated in a previous study by Castronovo et al. (13). They showed that pre-exposure of malignant murine cells to anti-Gal (these cells express an abundance of the Galal-3Gal/?l-4GlcNAc-R epitope) resulted in the subsequent in vivo trapping of the cells within the reticuloendothelial system, preventing metastasis formation. Theoretically, circulating malignant cells expressing this epitope in man would be eliminated by a similar mechanism mediated by anti-Gal. -
The study by Castronovo et al. raises several questions with regard to the possible in vivo interaction of anti-Gal and tumor cells. Does anti-Gal bind to mammary carcinoma cells in vivo? If so, does anti-Gal mediate an inflammatory response in vivo against cells expressing the Galal-3Gal01-4GlcNAc-R epitopes? If no such response is observed, how do the tumor cells compartmentalize themselves away from this abundant antibody? Does anti-Gal act as a barrier against metastasis formation by cells expressing the Galal-3Gal/51-4GlcNAc-R epitope, and if so, do the metastases of such primary tumors lack this carbohydrate epitope? Finally, the possibility exists of a transient decrease in the anti-Gal titer, which may hypothetically enable metastasis formation by cells expressing the Galal-3Gal/31-4GlcNAc-R epitope. This possibility should be examined. Careful studies of all of these questions in patients with malignant cells capable of binding anti-Gal may provide important information concerning the contribution of anti-Gal to the immune-mediated surveillance against malignant cells in man, as suggested by Castronovo et al.
